These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34867967)

  • 1. Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience.
    Balcerek J; Shy BR; Putnam AL; Masiello LM; Lares A; Dekovic F; Acevedo L; Lee MR; Nguyen V; Liu W; Paruthiyil S; Xu J; Leinbach AS; Bluestone JA; Tang Q; Esensten JH
    Front Immunol; 2021; 12():744763. PubMed ID: 34867967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System.
    Marín Morales JM; Münch N; Peter K; Freund D; Oelschlägel U; Hölig K; Böhm T; Flach AC; Keßler J; Bonifacio E; Bornhäuser M; Fuchs A
    Front Immunol; 2019; 10():38. PubMed ID: 30778344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function.
    Ou K; Hamo D; Schulze A; Roemhild A; Kaiser D; Gasparoni G; Salhab A; Zarrinrad G; Amini L; Schlickeiser S; Streitz M; Walter J; Volk HD; Schmueck-Henneresse M; Reinke P; Polansky JK
    Front Cell Dev Biol; 2021; 9():751590. PubMed ID: 34869339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product.
    Lavazza C; Budelli S; Montelatici E; Viganò M; Ulbar F; Catani L; Cannone MG; Savelli S; Groppelli E; Lazzari L; Lemoli RM; Cescon M; La Manna G; Giordano R; Montemurro T
    J Transl Med; 2022 Jan; 20(1):14. PubMed ID: 34986854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol.
    MacDonald KN; Ivison S; Hippen KL; Hoeppli RE; Hall M; Zheng G; Dijke IE; Aklabi MA; Freed DH; Rebeyka I; Gandhi S; West LJ; Piret JM; Blazar BR; Levings MK
    Cytotherapy; 2019 Dec; 21(12):1216-1233. PubMed ID: 31810768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods to manufacture regulatory T cells for cell therapy.
    MacDonald KN; Piret JM; Levings MK
    Clin Exp Immunol; 2019 Jul; 197(1):52-63. PubMed ID: 30913302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.
    Alsuliman A; Appel SH; Beers DR; Basar R; Shaim H; Kaur I; Zulovich J; Yvon E; Muftuoglu M; Imahashi N; Kondo K; Liu E; Shpall EJ; Rezvani K
    Cytotherapy; 2016 Oct; 18(10):1312-24. PubMed ID: 27497700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive Characteristics of Umbilical Cord Blood-derived Regulatory T Cells After Ex Vivo Expansion on Autologous and Allogeneic T Effectors and Various Lymphoblastic Cells.
    Vanichapol T; Pongsakul N; Srisala S; Apiwattanakul N; Chutipongtanate S; Hongeng S
    J Immunother; 2019 May; 42(4):110-118. PubMed ID: 30921263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T-cell therapy in transplantation: moving to the clinic.
    Tang Q; Bluestone JA
    Cold Spring Harb Perspect Med; 2013 Nov; 3(11):. PubMed ID: 24186492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis.
    Voskens CJ; Fischer A; Roessner S; Lorenz C; Hirschmann S; Atreya R; Neufert C; Atreya I; Neurath MF; Schuler G
    Inflamm Bowel Dis; 2017 Aug; 23(8):1348-1359. PubMed ID: 28708802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good Manufacturing Practice-Compliant Production and Lot-Release of
    Wiesinger M; Stoica D; Roessner S; Lorenz C; Fischer A; Atreya R; Neufert CF; Atreya I; Scheffold A; Schuler-Thurner B; Neurath MF; Schuler G; Voskens CJ
    Front Immunol; 2017; 8():1371. PubMed ID: 29123521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing.
    Eaker S; Armant M; Brandwein H; Burger S; Campbell A; Carpenito C; Clarke D; Fong T; Karnieli O; Niss K; Van't Hof W; Wagey R
    Stem Cells Transl Med; 2013 Nov; 2(11):871-83. PubMed ID: 24101671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
    Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
    Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Human Alloantigen-Specific Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy.
    Cheraï M; Hamel Y; Baillou C; Touil S; Guillot-Delost M; Charlotte F; Kossir L; Simonin G; Maury S; Cohen JL; Lemoine FM
    Cell Transplant; 2015; 24(12):2527-40. PubMed ID: 25198125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.